

PTO/SB/08b (09-06)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/524,278
		Filing Date	February 9, 2005
		First Named Inventor	SATO et al.
		Art Unit	1634
		Examiner Name	Jeanine Anne Goldberg
Sheet	1	of	1
		Attorney Docket Number	3190-074

RECEIVED  
CENTRAL FAX CENTER  
DEC 22 2006

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/JG/		HUANG et al., "Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese," Pharmacogenetics, 2000, Vol. 10, pp. 539-544.	

Examiner Signature	/Jeanine Goldberg/	Date Considered	02/05/2007
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM PTO-1449 (REV. 10-2000)	Atty. Docket No. 3190-074	Application No. 10/524,278
INFORMATION DISCLOSURE STATEMENT	APPLICANT: SATO et al.	
	Filing Date: February 9, 2005	Group Art Unit: Unassigned

APR 12 2005

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE, IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/JG/	Ito et al., "Effect of a Conserved Mutation in Uridine Diphosphate Glucuronosyltransferase 1A1 and 1A6 on Glucuronidation of a Metabolite of Flutamide," EUR. J. CLIN. PHARMACOL., Vol. 58, No. 1, pp. 11-14 (2002)
	Yamamoto et al., "Contribution of Two Missense Mutations (G71R and Y486D) of the Bilirubin UDP Glycosyltransferase (UGT1A1) Gene to Phenotypes of Gilbert's Syndrome and Crigler-Najjar Syndrome Type II," BIOCHIM. BIOPHYS. ACTA., Vol. 1406, No. 3, pp. 267-273 (1998)
	Ando et al., "Polymorphisms of UDP-Glucuronosyltransferase Gene and Irinotecan Toxicity: A Pharmacogenetic Analysis," CANCER RESEARCH, Vol. 60, pp. 6921-6926 (2000)
	Ando et al., "Polymorphisms and UDP-Glucuronosyltransferase and Pharmacokinetics of Irinotecan," THERAPEUTIC DRUG MONITORING, Vol. 24, pp. 111-116 (2002)
	Owens et al., "The Novel UGT1 Gene Complex Links Bilirubin, Xenobiotics, and Therapeutic Drug Metabolism by Encoding UDP-Glucuronosyltransferase Isozymes With a Common Carboxyl Terminus," JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, Vol. 24, No. 5, pp. 491-508 (1996)
	Jinno et al., "Glucuronidation of 7-Ethyl-10-Hydroxycamptothecin (SN-38), an Active Metabolite of Irinotecan (CPT-11), by Human UGT1A1 Variants, G71R, P229Q, and Y486D," DRUG METABOLISM AND DISPOSITION, Vol. 31, pp. 108-113 (2003)
	Gagné et al., "Common Human UGT1A Polymorphisms and the Altered Metabolism of Irinotecan Active Metabolite 7-Ethyl-10-Hydroxycamptothecin (SN-38)," MOLECULAR PHARMACOLOGY, Vol. 62, pp. 608-617 (2002)
	Chang et al., "Metabolism of Flutamide in Diet Control Fischer 344 and Brown Norway x F 344 Rats, and Its Hydroxylation and Conjugation by Human CYP450s and UDP-Glucuronosyltransferases," JOURNAL OF FOOD AND DRUG ANALYSIS, Vol. 8, No. 3, pp. 166-173 (2000)
↓	International Search Report for PCT/JP03/01475 mailed May 6, 2003

EXAMINER

/Jeanine Goldberg/

DATE CONSIDERED

02/05/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV 7-80)	Atty. Docket No. 3190-074	Page 1 of 1 Application No. 10/524,278
INFORMATION DISCLOSURE STATEMENT	Applicant: SATO et al.	
	Filing Date: February 9, 2005	Group Art Unit: <del>Unassigned</del> 1634

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE, IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/JG/	International Preliminary Examination Report for PCT/JP03/01475 mailed April 28, 2005 (English translation).
EXAMINER	/Jeanine Goldberg/
DATE CONSIDERED	02/05/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY